DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/lxx543/banzel__inovelon) has announced the addition of GlobalData's new report "Banzel / Inovelon (Epilepsy) - Forecast and Market Analysis to 2022" to their offering. PharmaPoint Drug Evaluation Report - Banzel / Inovelon (Epilepsy) - Forecast and Market Analysis to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action. Banzel (rufinamide) is an AED that was originally developed by Novartis. In 2004, Eisai acquired the rights to develop, manufacture, and market the … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/wnq5fc/pharmapoint) has announced the addition of GlobalData's new report "PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to 2022" to their offering. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action. Given India's large population of epilepsy patients, the AED market is fairly large, despite the relatively low cost of treatment. The main driver for growth in this market will be the continued uptake of recent AEDs, a growing middle … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/dbv6cf/pharmapoint) has announced the addition of GlobalData's new report "PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022" to their offering. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action. Due to China's vast general population, which drives the growth of the prevalent population of epilepsy patients, the AED market is fairly large, despite the relatively low cost of treatment. The main driver for growth in this market will … Continue reading →

The Advantages of having High-Functioning Autism and Asperger's Brandi, a girl with High-Functioning Autism, is going to tell you why she likes being on the autism spectrum ...http://www.AspergersSocialStories.com. By: Mark Hutten … Continue reading →

By Janice Wood Associate News Editor Reviewed by John M. Grohol, Psy.D. on March 14, 2013 New research shows that autism spectrum disorders (ASD) affect the brain activity of children and adults differently. We found that brain activity changes associated with autism do not just happen in childhood, and then stop, said Daniel Dickstein, M.D., director of the Pediatric Mood, Imaging and Neurodevelopment Program at Bradley Hospital in East Providence, R.I. Instead, our study suggests that they continue to develop, as we found brain activity differences in children with autism compared to adults with autism. Dickstein conducted a meta-analysis of pre-existing studies; this allowed the researcher team to directly compare the brain activity in children with autism versus adults with autism, according to Dickstein. The researchers conducted the study through Bradley Hospitals PediMIND Program. Started in 2007, the program seeks to identify biological and behavioral markers that could improve how children and adolescents are diagnosed and treated for psychiatric conditions. Using special computer games and brain scans including magnetic resonance imaging (MRI) Dickstein said he hopes to one day make the diagnosis and treatment of autism and other disorders more specific and effective. One of autisms most disabling symptoms is … Continue reading →

New research suggests that autism affects the brain differently as individuals with the developmental disorder age, a finding that may allow for a more targeted treatment approach. Using a new technique, researchers were able to directly compare the brain activity of kids and adults with autism. They found marked differences in brain activity depending on a persons age. We found that brain activity changes associated with autism do not just happen in childhood and then stop, said Daniel Dickstein of Brown University and Bradley Hospital who led the study published this month in the Journal of the American Academy of Child & Adolescent Psychiatry. Instead, our study suggests that they continue to develop This is the first study to show that. For the study, Dickstein and his colleagues looked at functional magnetic resonance imaging, or fMRI, brain scans that were conducted on children and adults with autism in previous studies. They found evidence of significantly more activity occurring in the minds of adults with autism as compared to children when the individuals were looking at faces and doing other social tasks, for example. The finding could have big implications for how autism is treated, researchers said. If we can identify … Continue reading →

Mar. 13, 2013 Autism results from abnormal cell communication. Testing a new theory, researchers at the University of California, San Diego School of Medicine have used a newly discovered function of an old drug to restore cell communications in a mouse model of autism, reversing symptoms of the devastating disorder. The findings are published in the March 13, 2013 issue of the journal PLOS ONE. "Our (cell danger) theory suggests that autism happens because cells get stuck in a defensive metabolic mode and fail to talk to each other normally, which can interfere with brain development and function," said Robert Naviaux, MD, PhD, professor of medicine and co-director of the Mitochondrial and Metabolic Disease Center at UC San Diego. "We used a class of drugs that has been around for almost a century to treat other diseases to block the 'danger' signal in a mouse model, allowing cells to return to normal metabolism and restore cell communication." "Of course, correcting abnormalities in a mouse is a long way from a cure for humans," said Naviaux, "but we are encouraged enough to test this approach in a small clinical trial of children with autism spectrum disorder in the coming year. This … Continue reading →

A drug that may reverse autism is to be tested on children with the condition, scientists have revealed. Preliminary results show that the drug, already used to treat sleeping sickness, corrects autism-like symptoms in mice. At the molecular level, it normalises faulty brain connections, cell-to-cell signalling, and metabolic effects thought to underlie the disorder. The drug, suramin, targets a cell messaging system that produces a metabolic response to stress. According to a new theory, autism is strongly linked to this pathway, known as purinergic signalling. Scientists in the US found that the drug corrected 17 types of abnormality linked to autism in genetically modified mice, including social behaviour problems. Autism is a wide ranging condition, mostly seen in boys, that affects a person's ability to socialise and communicate and can have a devastating lifelong impact. Around 600,000 children and adults in the UK are thought to have the disorder. Professor Robert Naviaux, co-director of the Mitochondrial and Metabolic Disease Centre at the University of California in San Diego, said: "Our theory suggests that autism happens because cells get stuck in a defensive metabolic mode and fail to talk to each other normally, which can interfere with brain development and function. … Continue reading →

Sparrow is Michigan's first certified Comprehensive Stroke Center Sparrow is one of America's best hospitals for stroke treatment. Learn more at sparrow.org/stroke. By: sparrowhealth … Continue reading →

Public release date: 13-Mar-2013 [ | E-mail | Share ] Contact: Mark Wheeler mwheeler@mednet.ucla.edu 310-794-2265 University of California - Los Angeles When someone has a stroke, time equals brain. The longer a stroke is left untreated, the more brain tissue is lost. Since the only proven treatment a clot-busting drug works in less than half of patients, stroke physicians had high hopes for a mechanical device that could travel through the blocked blood vessel to retrieve or break up the clot, restoring blood flow to the brain. But in a recently completed multi-site trial in which UCLA served as the clinical coordinating center, researchers found there was no overall recovery benefit to patients treated with clot-removal (embolectomy) devices, compared with standard post-stroke care, which includes monitoring blood pressure and ensuring the brain is receiving oxygen. The study also found that using brain scans to identify which patients might be the best candidates for embolectomy did not lead to better outcomes for those patients. The study was sponsored by the National Institutes of Health, and the results appeared in the March 7 edition of the New England Journal of Medicine. Treating an acute stroke is always a race against the clock, … Continue reading →